We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
+14.86%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$366M
AUM Growth
+$56.4M
Cap. Flow
+$27.5M
Cap. Flow %
7.51%
Top 10 Hldgs %
57.01%
Holding
57
New
4
Increased
13
Reduced
4
Closed
5

Top Buys

Rank Stock Value
1
CCXI
ChemoCentryx, Inc.
CCXI
+$13.3M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$8.76M
3
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$8.6M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.46M
5
AMGN icon
Amgen
AMGN
+$6.46M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$19.1M
2
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$8.98M
3
IMMU
Immunomedics Inc
IMMU
+$4.22M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$3.45M
5
BIIB icon
Biogen
BIIB
+$2.79M

Sector Composition

Rank Sector Weight
1 Healthcare 99.56%
2 Miscellaneous 0.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STRO icon
26
Sutro Biopharma
STRO
$353M
$3.01M 0.82%
13,933
– –
DCPH
27
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$2.85M 0.78%
50,000
+33,000
+194% +$1.96M
IOVA icon
28
Iovance Biotherapeutics
IOVA
$3.74B
$2.69M 0.74%
58,000
-87,000
-60% -$3.45M
ITCI
29
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.53M 0.69%
79,456
+54,656
+220% +$1.44M
NBIX icon
30
Neurocrine Biosciences
NBIX
$15.8B
$2.3M 0.63%
24,000
-197,800
-89% -$19.1M
ASND icon
31
Ascendis Pharma A/S
ASND
$16.4B
$2.3M 0.63%
13,800
– –
ALLK
32
DELISTED
Allakos
ALLK
$2.19M 0.6%
15,700
– –
BPMC
33
DELISTED
Blueprint Medicines
BPMC
$2.19M 0.6%
19,500
– –
FOLD
34
DELISTED
Amicus Therapeutics
FOLD
$2.19M 0.6%
94,600
– –
MRSN
35
DELISTED
Mersana Therapeutics
MRSN
$1.91M 0.52%
2,880
– –
ORIC icon
36
Oric Pharmaceuticals
ORIC
$1.42B
$1.79M 0.49%
+53,000
New +$1.52M
EXAS
37
DELISTED
Exact Sciences
EXAS
$1.42M 0.39%
10,700
– –
GWPH
38
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$1.18M 0.32%
10,200
– –
AXSM icon
39
Axsome Therapeutics
AXSM
$10.8B
$1.14M 0.31%
+14,000
New +$1.05M
NKTR icon
40
Nektar Therapeutics
NKTR
$2.55B
$1.14M 0.31%
4,467
– –
INSM icon
41
Insmed
INSM
$26.5B
$1.12M 0.31%
33,600
– –
AUPH icon
42
Aurinia Pharmaceuticals
AUPH
$2.19B
$1.08M 0.3%
78,500
-36,500
-32% -$531K
QURE icon
43
uniQure
QURE
$3.44B
$994K 0.27%
27,500
– –
GBT
44
DELISTED
Global Blood Therapeutics, Inc.
GBT
$944K 0.26%
21,800
– –
AGIO icon
45
Agios Pharmaceuticals
AGIO
$2.05B
$932K 0.25%
21,500
– –
KYNB
46
Kyntra Bio
KYNB
$32.4M
$731K 0.2%
788
– –
TVTX icon
47
Travere Therapeutics
TVTX
$6.36B
$545K 0.15%
+20,000
New +$467K
BLUE
48
DELISTED
bluebird bio
BLUE
$476K 0.13%
849
– –
ESPR
49
DELISTED
Esperion Therapeutics
ESPR
$247K 0.07%
9,500
– –
ANAB icon
50
AnaptysBio
ANAB
$1.7B
$215K 0.06%
10,000
– –
1
2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q4 2020 Portfolio in Review

As of Q4 2020, International Biotechnology Trust held 57 positions worth $366M, up 18% from $310M the previous quarter. Its ten largest holdings account for 57% of the portfolio.

International Biotechnology Trust deployed $27.5M of net new capital in Q4 2020, opening 4 new positions and adding to 13 existing holdings. Its largest new stake was Oric Pharmaceuticals: 53,000 shares worth $1.79M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $19.1M trimmed.

  • International Biotechnology Trust's largest Q4 2020 buy was Oric Pharmaceuticals: 53,000 shares worth $1.79M.
  • International Biotechnology Trust added most to ChemoCentryx, Inc. in Q4 2020, an estimated $13.3M increase.
  • International Biotechnology Trust's biggest Q4 2020 reduction was Neurocrine Biosciences, cutting an estimated $19.1M.
  • International Biotechnology Trust fully exited MyoKardia, Inc. Common Stock in Q4 2020, selling an estimated $8.98M.
  • International Biotechnology Trust's ten largest holdings make up 57% of its $366M portfolio in Q4 2020.
  • International Biotechnology Trust opened 4 new positions and closed 5 in Q4 2020.
  • International Biotechnology Trust's portfolio value rose 18% quarter-over-quarter to $366M.

Based on International Biotechnology Trust's 13F filing for Q4 2020, filed 19 Feb 2021.